Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 16INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Sarcoma 1CNS 1

Conditions

Breast Neoplasms 41Carcinoma, Renal Cell 32Neuroendocrine Tumors 15Neoplasms 12Neoplasm Metastasis 10Carcinoma, Non-Small-Cell Lung 8Carcinoma 7Tuberous Sclerosis 6Kidney Neoplasms 5Carcinoma, Hepatocellular 5Carcinoid Tumor 5Lymphoma 4Adenoma, Islet Cell 4Stomach Neoplasms 3Recurrence 3Pancreatic Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell 3Lymphangioleiomyomatosis 3Lung Neoplasms 3Colorectal Neoplasms 3Angiomyolipoma 3Adenocarcinoma 3von Hippel-Lindau Disease 2Triple Negative Breast Neoplasms 2Seizures 2Neuroectodermal Tumors, Primitive 2Lymphoproliferative Disorders 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2

Interventions

Dexamethasone 64Cyclophosphamide 35pomalidomide 34Lenalidomide 34Rituximab 31Bortezomib 30venetoclax 28fludarabine 27Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 17Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Injections 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × Everolimus × Clear all
NCT07062965 2026-05-06

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Pfizer

Phase 3 Recruiting
400 enrolled
Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Pfizer

Phase 2 Active not recruiting
333 enrolled
Breast

Breast Neoplasms, Recurrence

NCT03245151 2023-08-30

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

Eisai Inc.

Phase 1/2 Completed
64 enrolled 29 charts
CNSSarcoma

Glioma, Recurrence, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡